Supreme Court refuses Mylan's antitrust appeal; P.R. family claims Baxter tainted property;

@FiercePharma: Merck's Fosamax-suit score hits 3-1: Juries find for $MRK in all but one bellwether case. News | Follow @FiercePharma

> The U.S. Supreme Court refused to hear Mylan's appeal of a $77 million award to four insurers that said the company cornered the market on ingredients for anti-anxiety drugs. Report

> A Puerto Rican family has sued Baxter International, saying that a company warehouse contaminated their property with radioactive cobalt and other hazardous materials. Story

> Pozen issued a new revenue forecast after a district court upheld patents on its migraine drug Treximet. Story

> Dramatic increases in oral cancer since 1984 can be attributed to HPV infection, a new study found, with more than 70% of oral cancers now linked with the virus, compared with 16% in the 1980s. Item

> Increasing numbers of Medicare beneficiaries game the system to fill prescriptions for the painkillers and other narcotics they abuse. Report

> Florida officials offered an incentive package to Pharmacy South, a drugmaker that may establish a new manufacturing plant in the state. Report

> The most popular contraceptive for women in parts of Africa, a hormone shot, appears to double the risk of HIV infection. More

Biotech News

@FierceBiotech: AZ's MedImmune signs agreement with Pfizer for tremelimumab, a CTLA-4 monoclonal antibody that's a potential cancer treatment. Story | Follow @FierceBiotech

@ JohnCFierce: Mymetics "reclaims" flu vax from Solvay. $MYMX stock plunges 25% on the score, which means a loss of one cent. Release | Follow @JohnCFierce

@RyanMFierce: I caught up with four cool life sciences tech outfits with ties to the Boston area for my companies-to-watch report. Story | Follow @RyanMFierce

@MaureenFierce: Influenza pandemic prompts EMA vaccine quality rethink. Item | Follow @MaureenFierce

> Abbott venture arm takes lead on $20M Creabilis round. More

> Merck KGaA bolsters MS pipeline in $20M pact with Ono. News

Manufacturing News

> DHL, pharma group assess India's hobbled logistics. Story

> Hill Dermaceuticals enters consent decree with FDA. News

> Novo to enhance insulin in manufacturing/marketing strategy. Report

> Boehringer to launch biosimilars unit. Item

> FDA: Product quality issues fuel rise in drug shortages. Story

> Lonza readies as pharma sector boosts Singapore production. Article

Biotech Research News

> Pioneering Scripps scientist devotes a lifetime to addiction vaccines. Piece

> New mouse models open a window on autism research. Report

> Controversial XMRV study author fired from research post. More

> NIH kicks off $110M Knockout Mouse Project. Article

> Targeted treatment clears glioblastoma tumors in drug-resistant models. Story

> GSK's epigenetics team tests promising leukemia drug in mice. Item

And Finally... Lobbyists send patients and their stories to "super-committee" members considering Medicaid cuts. Report

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.